

## Board Meeting in Public Tuesday, 20 May 2025

<b>Title of Report</b>	Governance Update		<b>Agenda No.</b>	5.1
<b>Nature of Report</b>	<input checked="" type="checkbox"/> Official		<input type="checkbox"/> Official Sensitive	
<b>Author(s)</b>	Silena Dominy, Company Secretary			
<b>Lead Executive</b>	Helen Gillan, Director of Quality			
<b>Non-Executive Director Sponsor</b>	Peter Wyman, Chair			
<b>Presented for</b>	<input type="checkbox"/> Approval <input checked="" type="checkbox"/> Information <input type="checkbox"/> Assurance <input checked="" type="checkbox"/> Update			
<b>Executive Summary</b>				
This report provides the Board with an update on corporate governance matters in NHS Blood and Transplant (NHSBT).				
<b>Previously Considered by</b>				
N/A				
<b>Recommendation</b>	The Board is asked to note the report.			
<b>Risk(s) identified (Link to Board Assurance Framework Risks)</b>				
BAF P11 Corporate Governance "There is a risk that the Board do not have full oversight of significant risk caused by ineffective systems or their application resulting in uninformed decision-making, a requirement for emergency management, suboptimal outcomes and reputational damage" The frequent review of governance arrangements ensures continuous improvement and oversight. It reduces the likelihood of the Board not fulfilling its duties, or stepping outside of its powers, therefore strengthens governance.				
<b>Strategic Objective(s) this paper relates to:</b>				
<input checked="" type="checkbox"/> Collaborate with partners <input checked="" type="checkbox"/> Invest in people and culture <input type="checkbox"/> Drive innovation <input checked="" type="checkbox"/> Modernise our operations <input type="checkbox"/> Grow and diversify our donor base				
<b>Appendices:</b>				

## 1. Background

This report provides the Board with an update on Corporate Governance matters in NHSBT.

## 2. Board Level Policies

This meeting presents the following Board Level Policy for approval:

- Safeguarding and PREVENT: Management of the Vulnerable and At-Risk Policy (agenda item 4.1)

The Framework Agreement between DHSC and NHSBT is currently with DHSC awaiting ministerial approval.

Following the Board's consideration of the Standing Orders and Scheme of Delegations at their meeting on 1 April, the final form of these documents has been agreed offline as agreed with the Board. These can be found in the meeting Review Room.

## 3. Externally Facilitated Board Effectiveness Review

Following BDO LLP's presentation of their final report at the Board on 1 April, Directors have considered by exchange of emails the Board's response to the recommendations within the report. These have been summarised within the report to be considered under agenda item 5.1.1.

## 4. Board Appointments

Having completed two years as an Associate Non-Executive Director, Stephanie Itimi's term of office will end on 5 June 2025, and she will leave the Board at this time.

## 5. Stakeholder Engagement

Information in relation engagement of the Chair and Chief Executive with stakeholders and DHSC since the last meeting is included in the Convene Review Room.